Journal article
Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease
Sonali Shah, Cherie Chiang, Ken Sikaris, Zhong Lu, Bui Minh, Roger Zebaze, Ego Seeman
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | OXFORD UNIV PRESS INC | Published : 2017
DOI: 10.1210/jc.2016-3189
Abstract
Context: Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so suggest whether bone fragility is present. Methods: Concentrations of 25(OH)D, calcium, phosphate, creatinine, and parathyroid hormone (PTH) were measured in 11,855 participants. Serum C-terminal telopeptide of type 1 collagen, procollagen type 1 N-terminal propeptide (P1NP), aBMD, and distal ..
View full abstractGrants
Funding Acknowledgements
R.Z. has received grant and/or research support from Amgen, Merck Sharp & Dohme, Servier, Warner-Chilcott, AKP, Genzyme, Sanofi, GlaxoSmithKline, and Pfizer. He is a shareholder in StraxCorp, is remunerated by StraxCorp as president of research and development, and is one of the inventors of the StrAx1.0 algorithm. R.Z. is also a director on the board of StraxCorp. C.C. has received grant and/or research support from Amgen, Merck Sharp & Dohme, Servier, and Sanofi. E.S. has received research support and lectured at national and international meeting symposia funded by Allergan, Amgen, Asahi, Genzyme, and Merck Sharp & Dohme. He is a director of the board and shareholder in StraxCorp, is remunerated by StraxCorp as chief medical officer, and is one of the inventors of the StrAx1.0 algorithm. The remaining authors have nothing to disclose.